See personalized New Product recommendations! Get personalized New Product recommendations! Register or Login for personalized New Product recommendations!
Holiday Notification: Cayman Chemical will be closed Monday, May 28, 2012, in observance of the Memorial Day holiday.
More…
Please feel free to continue placing orders via our website or via fax at 734-971-3640. You may send an email to customer service at custserv@caymanchem.com , or to technical support at techserv@caymanchem.com which we will respond to the next business day. Cayman will resume regular business hours and shipping schedules on Tuesday, May 29, 2012. Thank you for your patience and understanding.
Chemical Class · Phospholipase
· See all 100+ product categories
| Item Number | Product | Sizes & Pricing | CAS | Purity | Image | Exclusive | Introduction Date | Mojo | Plain Text Name | Synonyms | Keywords | Interest |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62245 |
10- |
95864-17-8 | ≥98% |
|
32.651376192867 | 10-pyrene-pc | 1-Palmitoyl-2-pyrenedecanoyl Phosphatidylcholine | sPLA2s substrates fluorescent PLAs phospholipases fluorescence phospholipids | 32.651376192867 | |||
| 62235 |
1,2- |
89019-63-6 | ≥95% |
|
40.410214855739 | 1-2-bis-heptanoylthio-glycerophosphocholine | Diheptanoyl Thio-PC; 1,2-bis(Heptanoylthio)-1,2-dideoxy-sn-glycero-3-phosphorylcholine | sPLA2s iPLA2s substrates phospholipases PLAs sn-2 cleavage lysophosholipids DTNB DTB detection | 40.410214855739 | |||
| 62260 |
2- |
3443-82-1 | >98% |
|
✓ | 18.476045777426 | 2-linoleoyl-glycerol | 2-LG | CB1 glycerols 2LG cannabinoids 2-Linoleoyl-Glycerol reuptake endocannabinoids receptors congeners fatty acids neurochemistry neuroscience lipids cannabinoids cbs synthetic | 18.476045777426 | ||
| 60925 |
2- |
- | >98% |
|
19.089171270718 | 2-o-ethyl-paf-c-16 | platelet-activating factors PAFs analogs agonists | 19.089171270718 | ||||
| 60902 |
2- |
78858-44-3 | >98% |
|
10.577513812155 | 2-o-methyl-paf-c-16 | PAFs platelet-activating factors analogs methyl inhibits inhibitors tumors cells | 10.577513812155 | ||||
| 60912 |
2- |
77286-66-9 | >98% |
|
6.188022099447 | 2-o-methyl-paf-c-18 | Edelfosine; ET-18-OCH3; 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphorylcholine | PAFs platelet-activating factors anticancer analogs | 6.188022099447 | |||
| 10005707 |
(2S)- |
- | ≥98% |
|
2005-10-19 | 33.258149171270 | -2s-ompt | GPR lysophosphatidic acids lipids mediators receptors LPA1/Edg-2 LPA2/Edg-4 LPA3/Edg-7 LPA4/GPR23 agonists calcium mobilization Sf9 cells (2R)-OMPT release assays LPA3-transfected rat hepatoma Rh7777 | 33.258149171270 | |||
| 60945 |
2- |
96801-55-7 | ≥98% |
|
39.283701657458 | 2-thio-paf | 2-thio-PAFs platelet-activating factors PAF-AH substrates agonists analogs PAF-acetylhydrolases receptors lysophospholipases | 39.283701657458 | ||||
| 62910 |
7- |
161180-11-6 | ≥98% |
|
✓ | 30.091171270718 | 7-hydroxycoumarinyl-arachidonate | Umbelliferyl Arachidonate | fluorescent cPLA2s substrates 7-hydroxycoumarin fluorescence PLAs phospholipases 7-OH-coumarin fatty acids | 30.091171270718 | ||
| 10556 |
7- |
161180-12-7 | ≥98% |
|
2010-11-03 | 2.670828729282 | 7-hydroxycoumarinyl-linolenate | Umbelliferyl-γ-Linolenate | 7-HC-γ-linolenate 7-HC-gamma-linolenate 7-HC-.gamma.-linolenate 7-HC-g-linolenate 7-hydroxy coumarin seven 7 hydroxy gamma .gamma. g γ substrates fluorogenic cPLAs cPLA2 phospolipase fatty acids FAAH enzyme activities activity | 2.670828729282 | ||
| 60904 |
Arachidonoyl PAF C- |
86288-11-1 | >98% |
|
6.211408839779 | arachidonoyl-paf-c-16 | 1-O-hexadecyl-2-Arachidonoyl-sn-glycero-3-Phosphocholine | PAFs platelet-activating factors arachidonic | 6.211408839779 | |||
| 62240 |
Arachidonoyl thio- |
146797-82-2 | >98% |
|
30.393586137619 | arachidonoyl-thio-pc | 2-deoxy-2-thio Arachidonoyl PC | sPLA2s iPLA2s cPLA2s AT-PC substrates phospholipases cytosolic secretory calcium-independent PLAs | 30.393586137619 | |||
| 62120 | Arachidonyl Trifluoromethyl Ketone | 149301-79-1 | >98% |
|
27.837851442603 | arachidonyl-trifluoromethyl-ketone | ATK; AATFMK | ATK AACOCF3 inhibitors PLA2 analogs fatty acids lipoxygenases inhibition inhibits LOs neurochemistry neuroscience | 27.837851442603 | |||
| 10803 | Autotaxin (human recombinant) | - | ≥95% |
|
2011-04-04 | 14.860662983425 | autotaxin-human-recombinant | Ectonucleotide Pyrophosphatase/Phosphodiesterase-2; Lysophospholipase D; ENPP-2 | lipids hydrolysis lysophophatidyl choline lysophophatidic acids secreated glycosylated active | 14.860662983425 | ||
| 60924 | Azelaoyl PAF | - | >98% |
|
43.427316495658 | azelaoyl-paf | PPAR gamma oxidized LDL lipids agonist atherosclerosis nuclear receptors | 43.427316495658 | ||||
| 70700 | Bromoenol lactone | 88070-98-8 | >98% |
|
45.099250197316 | bromoenol-lactone | Haloenol lactone; HELSS; BEL | selective iPLA2 inhibitors phospholipases PLAs | 45.099250197316 | |||
| 9000528 |
Bromoenol lactone- |
- | ≥99% deuterated forms (d1-d7) |
|
2010-06-21 | 15.601223362273 | bromoenol-lactone-d7 | Haloenol lactone-d7; HELSS-d7; BEL-d7 | selective iPLA2 inhibitors phospholipases PLAs deuterateds deuterium GC/MS GC-MS LC/MS LC-MS mass spectrometry MS inhibited inhibition | 15.601223362273 | ||
| 60928 | Butanoyl PAF | - | >98% |
|
5.806546961326 | butanoyl-paf | ox-LDL signaling molecules oxLDL oxidized low-density lipoproteins PMNL polymorphonuclear leukocytes platelet-activating factors atherosclerosis | 5.806546961326 | ||||
| 60929 | Butenoyl PAF | - | >98% |
|
3.819160220994 | butenoyl-paf | ox-LDL signaling molecules oxLDL oxidized low-density lipoproteins PMNL polymorphonuclear leukocytes platelet-activating factors atherosclerosis | 3.819160220994 | ||||
| 765021 | cPLA2 Assay Kit | - |
|
137.165624999999 | cpla2-assay-kit | PLA2 Type IV Assay Kit; Calcium-dependent Cytosolic Phospholipase A2 Assay Kit | phospholipases inflammation eicosanoids colorimetric kits assays cPLA2s enzymes analysistools:cpla2 | 137.165624999999 | ||||
| 10009181 |
CREB (Phospho- |
- | 2006-09-26 | 4.175996986439 | creb-phospho-ser133-polyclonal-antibody | antibodies proteins diseases antibodies antisera antiserum WB western blots blotting cyclic AMP response element binding proteins transcription factors intracellular signaling kinases phosphorylate phosphorylation phospho-specific immunoblotting | 4.175996986439 | |||||
| 60901 |
Dihomo- |
155575-01-2 | >98% |
|
5.288756906077 | dihomo-linolenoyl-paf-c-16 | 1-O-hexadecyl-2-dihomo-γ-Linolenoyl-sn-glycero-3-Phosphocholine | PAFs platelet-activating factors Dihomo-gamma-Linolenoyl dihomo-g-linolenyl dihomo-.gamma.-linolenoyl | 5.288756906077 | |||
| 60903 |
Docosahexaenoyl PAF C- |
132213-85-5 | ≥98% |
|
5.288756906077 | docosahexaenoyl-paf-c-16 | PAFs platelet-activating factors DHA | 5.288756906077 | ||||
| 60907 |
Eicosapentaenoyl PAF C- |
132196-28-2 | ≥98% |
|
4.846201657458 | eicosapentaenoyl-paf-c-16 | PAFs platelet-activating factors EPA | 4.846201657458 | ||||
| 10009179 |
ERK/MAPK (Phospho- |
- | 2006-09-26 | 4.436996484178 | erk-mapk-phospho-thr202-tyr204-polyclonal-antibody | antibodies proteins diseases antibodies antisera antiserum WB western blots blotting extracellular-signal related kinase/mitogen-activated proteins signaling mitogenesis mitotic cells learning memory phosphorylation phospho-specific immunoblotting | 4.436996484178 | |||||
| 13179 | FKGK 11 | 1071000-98-0 | ≥98% |
|
2009-06-30 | 21.816983425414 | fkgk-11 | Phospholipases A2 iPLA2 inhibitors signal transduction inhibition PLAs | 21.816983425414 | |||
| 10006695 | HEPC | 60793-01-3 | ≥95% |
|
2005-03-29 | 3.870508287293 | hepc | 2-Hexadecanoylthio-1-Ethylphosphorylcholine | PLA2 phospholipases substrates thiesters PL Ellman's reagent colorimetric analogs glyceerophospholipids activity phosphatidylcholine Type II porcine pancreatic bee venoms snake | 3.870508287293 | ||
| 60905 |
Hexanolamino PAF C- |
137566-83-7 | ≥98% |
|
5.288756906077 | hexanolamino-paf-c-16 | PAFs platelet-activating factors analogs hexanolamino antagonists ROS reactive oxygen species | 5.288756906077 | ||||
| 160507 | iPLA2 (Type VI) Polyclonal Antibody | - | 76.158309392264 | ipla2-type-vi-polyclonal-antibody | Calcium-independent Phospholipase A2 | phospholipases antisera western blots blotting WB antibodies antiserum immunoblotting | 76.158309392264 | |||||
| 60906 |
Lyso- |
52691-62-0 | >98% |
|
5.767182320442 | lyso-paf-c-16 | PAFs platelet-activating factors | 5.767182320442 | ||||
| 360906 |
Lyso- |
- | ≥99% deuterated forms (d1-d4) |
|
5.767182320442 | lyso-paf-c-16-d4 | Lyso-Platelet-activating Factor C-16-d4 | PAFs deuterium GC/MS internal isotopes deuterated lyso-PAF-C-16-d4 standards GC-MS LC/MS LC-MS mass spectrometry platelet-activating factors | 5.767182320442 | |||
| 60916 |
Lyso- |
74430-89-0 | ≥98% |
|
3.363342541436 | lyso-paf-c-18 | PAFs platelet-activating factors | 3.363342541436 | ||||
| 10010228 |
Lyso- |
- | ≥99% deuterated forms (d1-d4) |
|
✓ | 2010-11-03 | 18.899071823204 | lyso-paf-c-18-d4 | PAFs platelet-activating factors deuterateds deuterium mass spectrometry MS LC/MS GC/MS LC-MS GC-MS | 18.899071823204 | ||
| 10005375 | Lysophospholipase D Polyclonal Antibody | - | 2005-05-11 | 22.818281767955 | lysophospholipase-d-polyclonal-antibody | Autotaxin; lysoPLD; ENPP2 | proteins antibodies antisera antiserum wb western blots blotting ICC immunocytochemistry LPA lysophosphatidic acids extracellular signals signalling lipids platelets aggregation smooth muscle contractions cell proliferations chemotaxis lysophosphatidylcholines LPC autocine motility factors autotaxins ATX tumor progression metastasis mRNA glycosylated SDS-PAGE immunoblotting | 22.818281767955 | ||||
| 10009178 |
MEK1/2 (Phospho- |
- | 2006-09-26 | 0.937101572460 | mek1-2-phospho-ser218-222-polyclonal-antibody | MAP Kinase Kinase 1/2; MAPKK1/2 | antibodies proteins diseases antibodies antisera antiserum WB western blots blotting MAP kinases MKK cascades cell growth differentiation synaptic plasticity brain phosphorylating phospho-specific immunoblotting | 0.937101572460 | ||||
| 70660 | Methyl Arachidonyl Fluorophosphonate | 188404-10-6 | ≥98% |
|
84.365923879680 | methyl-arachidonyl-fluorophosphonate | MAFP | phospholipases inhibitors cPLA2 iPLA2 MAFP fatty acids neuroscience neurochemistry | 84.365923879680 | |||
| 60908 |
Methylcarbamyl PAF C- |
91575-58-5 | >98% |
|
30.302860650706 | methylcarbamyl-paf-c-16 | PAFs platelet-activating factors analogs agonists | 30.302860650706 | ||||
| 70662 |
Methyl α- |
- | ≥98% |
|
20.089707971586 | methyl-linolenyl-fluorophosphonate | MLnFP | PLA2s phospholipases A2 FAAH fatty acids amides hydrolase inhibitors cannabinoids CB receptors antagonists analogs MAFP MaLnFP M.alpha.LnFP MalphaLnFP alpha-linolenyl .alpha.-linolenyl neurochemistry neuroscience | 20.089707971586 | |||
| 70560 | Oleyloxyethyl Phosphorylcholine | 84601-19-4 | ≥98% |
|
19.847928176795 | oleyloxyethyl-phosphorylcholine | phospholipase inhibitors | 19.847928176795 | ||||
| 10009177 |
p38 MAPK (Phospho- |
- | 2006-09-26 | 4.369298767531 | p38-mapk-phospho-thr180-tyr182-polyclonal-antibody | Anti-Phospho-Thr180/Tyr182 p38 MAPK | antibodies proteins diseases antibodies antisera antiserum WB western blots blotting phospho-specific immunoblotting | 4.369298767531 | ||||
| 760901 | PAF Acetylhydrolase Assay Kit | - |
|
110.877645027623 | paf-acetylhydrolase-assay-kit | PAF-AH; Lp-PLA2 | PAF-AH colorimetric phospholipids atherosclerosis cytosolic extracellular platelet-activating factors PAFs enzymes analysistools:cytpafah analysistools:expafah assays paf elisa kit | 110.877645027623 | ||||
| 360603 | PAF Acetylhydrolase Blocking Peptide | - | 6.615027624309 | paf-acetylhydrolase-blocking-peptide | PAF-AH; Lp-PLA2; Platelet-activating Factor Acetylhydrolase | western blots blotting controls peptides acetyl hydrolases IHC immunohistochemistry PAF-AH PAFs platlet-activating factors antibodies | 6.615027624309 | |||||
| 160603 | PAF Acetylhydrolase (human) Polyclonal Antibody | - |
|
10.591215469613 | paf-acetylhydrolase-human-polyclonal-antibody | Platelet-activating Factor Receptor Acetylhydrolase; PAF-AH; Lp-PLA2 | atherosclerosis platelet-activating factors Western blots asthma inflammation preeclampsia antisera PAFs WB antibodies antiserum blotting immunoblotting | 10.591215469613 | ||||
| 10279 | PAF Acetylhydrolase (human recombinant) | - | ≥95% |
|
2008-06-19 | 20.216393054459 | paf-acetylhydrolase-human-recombinant | Lp-PLA2; PAF-AH; Platelet-Activating Factor Acetylhydrolase; Lipoprotein PLA2 | proteins PAFs lipids mediator inflammation PAFAH enzymes PAF AH phospholipases PLA2s inflammatory N-terminal His-tags His-tagged active | 20.216393054459 | ||
| 10010081 | PAF Acetylhydrolase (human) Western Ready Control | - |
|
2007-05-30 | 2.592640883977 | paf-acetylhydrolase-human-western-ready-control | PAF-AH; Lp-PLA2; Platelet-activating Factor Acetylhydrolase; Lipoprotein PLA2 | western blotting WB atherosclerosis factors asthma inflammation PAFs | 2.592640883977 | |||
| 10004380 | PAF Acetylhydrolase Inhibitor Screening Assay Kit | - | 2004-03-29 | 47.752897483117 | paf-acetylhydrolase-inhibitor-screening-assay-kit | PAF-AH Inhibitor Screening Assay Kit; Lp-PLA2 Inhibitor Screening Assay Kit | platelet-activating factors hypotension inflammations allergys PAFAH atherosclerosis heart diseases measures kits inhibitors PAFs assays paf elisa kit | 47.752897483117 | ||||
| 60900 |
PAF C- |
74389-68-7 | >98% |
|
13.996712707182 | paf-c-16 | Platelet-activating Factor C-16 | PAFs platelet-activating factors atherosclerosis | 13.996712707182 | |||
| 360900 |
PAF C- |
- | ≥99% deuterated forms (d1-d4) |
|
16.246022099448 | paf-c-16-d4 | Platelet-activating Factor C-16-d4 | PAFs deuterium GC/MS internal isotopes deuterated PAF-C-16-d4 standards GC-MS LC/MS LC-MS mass spectrometry platelet-activating factors atherosclerosis | 16.246022099448 | |||
| 60910 |
PAF C- |
74389-69-8 | >97% |
|
17.985480662983 | paf-c-18 | PAFs platelet-activating factors atherosclerosis | 17.985480662983 | ||||
| 10010229 |
PAF C- |
- | ≥99% deuterated forms (d1-d4) |
|
✓ | 2010-11-03 | 18.859116022099 | paf-c-18-d4 | PAFs platelet-activating factors atherosclerosis deuterateds deuterium mass spectrometry MS LC/MS GC/MS LC-MS GC-MS | 18.859116022099 | ||
| 360600 | PAF Receptor Blocking Peptide (Monoclonal) | - | 24.496256906077 | paf-receptor-blocking-peptide-monoclonal | Platelet-activating Factor | platelet-activating factors PAFs ICC immunocytochemistry flow cytometry FACS receptors peptides controls antibodies lipids PAFR | 24.496256906077 | |||||
| 160604 | PAF Receptor Blocking Peptide (Polyclonal) | - | ~30% | 10.862265193371 | paf-receptor-blocking-peptide-polyclonal | Platelet-activating Factor Receptor | platelet-activating factors Western blots controls peptides asthma inflammation receptors PAFs antibodies PAFR | 10.862265193371 | ||||
| 160600 | PAF Receptor (human) Monoclonal Antibody (11A4, Clone 21) | - | 21.703878453038 | paf-receptor-human-monoclonal-antibody-11a4-clone-21 | Platelet-activating Factor Receptor | platelet-activating factors antibodies PAFs ICC immunocytochemistry antisera antiserum flow cytometry FACS receptors atherosclerosis PAFR FC | 21.703878453038 | |||||
| 160602 | PAF Receptor (human) Polyclonal Antibody | - |
|
27.475944751381 | paf-receptor-human-polyclonal-antibody | Platelet-activating Factor Receptor | platelet-activating factors antisera PAFs antiserum antibodies flow cytometry facs immunocytochemistry icc western blots blotting wb atherosclerosis PAFR FC immunoblotting | 27.475944751381 | ||||
| 62650 | Palmityl Trifluoromethyl Ketone | 141022-99-3 | >98% |
|
43.213038674033 | palmityl-trifluoromethyl-ketone | PTK; Pentadeca Trifluoromethyl Ketone | ketones inhibitors analogs palmitic fatty acids inhibits inhibition lipoxygeanses LOs neurochemistry neuroscience | 43.213038674033 | |||
| 60909 |
Pyrrolidino PAF C- |
91021-63-5 | >98% |
|
10.577513812155 | pyrrolidino-paf-c-16 | platelet-activating factors PAFs analogs agonists | 10.577513812155 | ||||
| 10006800 |
(R)- |
478288-90-3 | ≥98% |
|
✓ | 2005-05-31 | 12.755395948434 | -r-bromoenol-lactone | (R)-BEL | selective iPLA2 inhibitors phospholipases PLAs BEL iPLA2b iPLA2.beta. iPLA2g iPLA2.gamma. lipids hydrolases cells signaling digestion membrane remodeling venom calcium independent releases AA arachidonic acids physiologic stimuli irreversible chiral mechanism-based human recombinants | 12.755395948434 | |
| 10534 |
(R)- |
- | ≥99% deuterated forms (d1-d7) |
|
✓ | 2010-06-17 | 7.613259668508 | -r-bromoenol-lactone-d7 | (R)-BEL-d7 | selective iPLA2 inhibitors phospholipases PLAs BEL iPLA2b iPLA2.beta. iPLA2g iPLA2.gamma. lipids hydrolases cells signaling digestion membrane remodeling venom calcium independent releases AA arachidonic acids physiologic stimuli irreversible chiral mechanism-based human recombinants deuterium deuterateds GC/MS LC/MS LC-MS GC-MS mass spectrometry MS signalling standards | 7.613259668508 | |
| 10006801 |
(S)- |
478288-94-7 | ≥98% |
|
2005-05-31 | 12.718747697974 | -s-bromoenol-lactone | (S)-BEL | selective iPLA2 inhibitors phospholipases PLAs BEL iPLA2b iPLA2.beta. iPLA2g iPLA2.gamma. lipids hydrolases cells signaling digestion membrane remodeling venom calcium independent releases AA arachidonic acids physiologic stimuli irreversible chiral mechanism-based vasopression-induced rat aortic smooth muscle A10 | 12.718747697974 | ||
| 10535 |
(S)- |
- | ≥99% deuterated forms (d1-d7) |
|
✓ | 2010-06-17 | 8.306298342541 | -s-bromoenol-lactone-d7 | (S)-BEL-d7 | selective iPLA2 inhibitors phospholipases PLAs BEL iPLA2b iPLA2.beta. iPLA2g iPLA2.gamma. lipids hydrolases cells signaling digestion membrane remodeling venom calcium independent releases AA arachidonic acids physiologic stimuli irreversible chiral mechanism-based vasopression-induced rat aortic smooth muscle A10 deuterium deuterateds GC/MS GC-MS LC/MS LC-MS mass spectrometry MS signalling standards | 8.306298342541 | |
| 10004913 | sPLA2 Assay (human Type V) | - | 2004-05-17 | 6.244364640883 | spla2-assay-human-type-v | 6.244364640883 | ||||||
| 765001 | sPLA2 Assay Kit | - |
|
92.274765793898 | spla2-assay-kit | Secretory Phospholipase A2 (Type IIA) Assay Kit | phospholipases inflammation eicosanoids colorimetric assays kits sPLA2s enzymes analysistools:spla2 | 92.274765793898 | ||||
| 10009563 | sPLA2 (human recombinant Type V) | - | ≥95% | 2007-01-16 | 26.160939226518 | spla2-human-recombinant-type-v | Secretory Phospholipase A2 (Group V); gVPLA2 | proteins binding enzymes secretory phospholipases recombinant E. coli catalyzes hydrolysis fatty acids sn-2 glycerophospholipids isoforms arachidonic mobilization macrophages mast cells golgi apparatus nuclear envelope plasma membranes murine bone marrow-derived rat mouse heart lung placenta spleen P388D1 electrophoresis coomassie staining active | 26.160939226518 | |||
| 485009 | sPLA2 (human Type IIA) Affinity Sorbent | - | 30.071602209944 | spla2-human-type-iia-affinity-sorbent | Secretory Phospholipase A2 (human synovial) | phospholipases purifications purify sorbents eias enzyme immunoassays reagents spla2s samples matrix resins | 30.071602209944 | |||||
| 160500 | sPLA2 (human Type IIA) Monoclonal Antibody (Clone SCACC353) | - |
|
27.568201350522 | spla2-human-type-iia-monoclonal-antibody-clone-scacc353 | Secretory Phospholipase A2 (human synovial) | phospholipases arthritis inflammation antibodies western blots blotting WB antisera antiserum immunoprecipitation IP immunoblotting | 27.568201350522 | ||||
| 160502 | sPLA2 (human Type IIA) Polyclonal Antiserum | - | 44.020142067876 | spla2-human-type-iia-polyclonal-antiserum | Secretory Phospholipase A2 (human synovial) | phospholipases arthritis inflammation antisera western blots blotting WB antibodies antiserum immunoprecipitation IP immunohistochemistry IHC immunoblotting | 44.020142067876 | |||||
| 10011382 | sPLA2 (human Type IIA) Western Ready Control Exclusive | - | ✓ | 2008-03-17 | 33.505856353591 | spla2-human-type-iia-western-ready-control | Secretory Phospholipase A2 (human Type IIA); sPLA2 (human synovial) | WB western blots blotting immunoblotting | 33.505856353591 | |||
| 160510 |
sPLA2 (human Type V) Monoclonal Antibody (Clone MCL- |
- |
|
24.582608962553 | spla2-human-type-v-monoclonal-antibody-clone-mcl-3g1 | gVPLA2; Secretory Phospholipase A2 (human Group V) | group phospholipases antibodies western blots blotting recombinant WB antisera antiserum immunoblotting Enzyme-linked immunosorbent assays IHC immunohistochemistry | 24.582608962553 | ||||
| 10009739 | sPLA2 (human type V) Western Ready Control | - | 2007-05-25 | 13.856261510128 | spla2-human-type-v-western-ready-control | sPLA2 (group V); gVPLA2 | western blotting WB controls antibodies antisera antiserum phospholipases sPLA2s group secretory monoclonal | 13.856261510128 | ||||
| 160512 | sPLA2 (mouse Type V) Polyclonal Antibody | - |
|
21.413839779005 | spla2-mouse-type-v-polyclonal-antibody | Secretory Phospholipase A2 (mouse group V) | antibodies spla2s phospholipases mouse western blots blotting WB antisera antiserum sPLA2 gV immunoblotting | 21.413839779005 | ||||
| 360512 | sPLA2 (murine Type V) Blocking Peptide | - | >50% | 2.250441988950 | spla2-murine-type-v-blocking-peptide | Secretory Phospholipase A2 | antibodies spla2s phospholipases mouse western blots blotting WB control peptides group V | 2.250441988950 | ||||
| 60500 | sPLA2 (Type III) | 9001-84-7 | 20-50% based on SDS-PAGE analysis; may contain melittin of unknown percentage | 48.583635359116 | spla2-type-iii | Secretory Phospholipase A2 (bee venom) | phospholipases A2 enzymes bees extracellular calcium dependent active | 48.583635359116 | ||||
| 10004883 | sPLA2 (Type V) Inhibitor Screening Assay Kit | - | 2004-05-07 | 52.717553275453 | spla2-type-v-inhibitor-screening-assay-kit | Secretory Phospholipase A2 (Type V) | assays measures kits inhibition inhibitors phospholipases inflammation eicosanoids colorimetric sPLA2s enzymes diheptanoyl thio-pc | 52.717553275453 | ||||
| 81590 | Staurosporine | 62996-74-1 | >98% |
|
21.359733917571 | staurosporine | Stsp | inhibitor inhibits protein kinase pkc-alpha pkc-.alpha. eNOS endothelial nitric oxide synthases | 21.359733917571 | |||
| 10007565 | Tetradecyl Phosphonate | 4671-75-4 | >98% |
|
2005-10-17 | 49.791160220994 | tetradecyl-phosphonate | pan-antagonists LPA receptors lysophosphatic acids lipids signalling molecules hydrolysis lysophospholipase D autotoxin signals GPCRs G-protein coupled LPA1/EDG-2 LPA2/EDG-4 LPA3/EDG-7 LPA4/GPR23 activates activation PPAR.gamma. peroxisomes proliferator-activated inhibits inhibition LPA-induced calcium mobilization activates reporter | 49.791160220994 | |||
| 60950 |
(±)trans- |
116673-45-1 | ≥98% |
|
4.326817679558 | -trans-2-5-bis-3-4-5-trimethoxyphenyl-1-3-dioxolane | trans-BTP Dioxolane | PAFs antagonists dioxolanes receptors platelet-activating factors (±)trans-2,4-bis-(3,4,5-Trimethoxyphenyl)-1,3-dioxolane | 4.326817679558 | |||
| 70740 |
U- |
112648-68-7 | ≥97% |
|
48.615801104973 | u-73122 | inhibitors inhibits PLC phospholipases C HIV-1 integrase u73122 | 48.615801104973 | ||||
| 10009180 |
β- |
- | 2006-09-26 | 1.623093922652 | -catenin-phospho-ser33-37-polyclonal-antibody | Anti-Phospho-Ser33,37 β-Catenin | antibodies proteins diseases antibodies antisera antiserum WB western blots blotting cadherin cells adhesion neural Wingless/Wnt signaling pathways hyperphosphorylation glycogen synthases kinases 3.beta. GSK3.beta. 3b cancers phospho-specific immunoblotting | 1.623093922652 | ||||
| 10006579 |
γ- |
16326-32-2 | >98% |
|
2005-03-04 | 4.030134175216 | -linolenic-acid-methyl-ester | γ-Linolenic Acid methyl ester; Methyl GLA; Methyl γ-Linolenate | fatty acids PUFAs gamma-linolenic g-linolenic .omega.-6 omega-6 .gamma.-linolenic polyunsaturated defiency diets bronchioconstriction | 4.030134175216 |
Cayman Chemical Company · 1180 East Ellsworth Road · Ann Arbor, Michigan 48108 · USA
Toll Free: (800) 364-9897 (USA and Canada Only) · Fax: (734) 971-3640
Copyright 2012 Cayman Chemical Company
Quick Search